Cargando…

The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients

Background: Bevacizumab combined with chemotherapy is still one of the standard options for treatment of advanced non-small cell lung cancer (NSCLC) patients without driver mutations. Serum inflammatory factors, representing the systemic immune status, are shown to have complicated relationships wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Butuo, Wang, Shijiang, Li, Cheng, Guo, Meiying, Xu, Yiyue, Sun, Xindong, Yu, Jinming, Wang, Linlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775608/ https://www.ncbi.nlm.nih.gov/pubmed/31602260 http://dx.doi.org/10.7150/jca.30478

Ejemplares similares

Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC
por: Li, Butuo, et al.
Publicado: (2018)

Delineating the pattern of treatment for elderly locally advanced NSCLC and predicting outcomes by a validated model: A SEER based analysis
por: Guo, Meiying, et al.
Publicado: (2019)

Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer
por: Zhao, Qian, et al.
Publicado: (2021)

Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases
por: Shang, Shuheng, et al.
Publicado: (2018)

Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review
por: Liu, Zhichao, et al.
Publicado: (2018)

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer
por: Li, Butuo, et al.
Publicado: (2022)

Multiple Immune Features-Based Signature for Predicting Recurrence and Survival of Inoperable LA-NSCLC Patients
por: Guo, Meiying, et al.
Publicado: (2020)

Prognostic Value of a Nomogram Based on the Dynamic Albumin-to-Alkaline Phosphatase Ratio for Patients with Extensive-Stage Small-Cell Lung Cancer
por: Li, Butuo, et al.
Publicado: (2020)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
por: Li, Butuo, et al.
Publicado: (2021)

Extramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review
por: Bao, Youting, et al.
Publicado: (2018)

Development and validation of a risk prediction model for radiotherapy-related esophageal fistula in esophageal cancer
por: Xu, Yiyue, et al.
Publicado: (2019)

A novel deep learning prognostic system improves survival predictions for stage III non‐small cell lung cancer
por: Yang, Linlin, et al.
Publicado: (2022)

Integrating Clinical Data and Attentional CT Imaging Features for Esophageal Fistula Prediction in Esophageal Cancer
por: Xu, Yiyue, et al.
Publicado: (2021)

NcRNAs-mediated P2RX1 expression correlates with clinical outcomes and immune infiltration in patients with breast invasive carcinoma
por: Xu, Yiyue, et al.
Publicado: (2022)

Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
por: Mu, Fengchun, et al.
Publicado: (2023)

Integrated multi-dimensional deep neural network model improves prognosis prediction of advanced NSCLC patients receiving bevacizumab
por: Li, Butuo, et al.
Publicado: (2023)

Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases
por: Li, Butuo, et al.
Publicado: (2020)

Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy
por: Wen, Qiang, et al.
Publicado: (2017)

Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer
por: Yang, Jingru, et al.
Publicado: (2022)

Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer
por: Li, Xuanzong, et al.
Publicado: (2022)

Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed
por: Nasha, Zhang, et al.
Publicado: (2017)

Correction: Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed
por: Zhang, Nasha, et al.
Publicado: (2017)

Effects of respiratory motion on volumetric and positional difference of GTV in lung cancer based on 3DCT and 4DCT scanning
por: Wang, Shijiang, et al.
Publicado: (2019)

Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review
por: Wang, Haiyong, et al.
Publicado: (2016)

Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report
por: Ding, Xingchen, et al.
Publicado: (2017)

Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma
por: Li, Xuanzong, et al.
Publicado: (2021)

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
por: Li, Xuanzong, et al.
Publicado: (2021)

Prophylactic cranial irradiation-related lymphopenia affects survival in patients with limited-stage small cell lung cancer
por: Fan, Xinyu, et al.
Publicado: (2023)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
por: Zhao, Zhiting, et al.
Publicado: (2023)

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Bevacizumab treatment for advanced non-small cell lung cancer: A case report
por: FAN, YUN, et al.
Publicado: (2013)

Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review
por: Chen, Dawei, et al.
Publicado: (2015)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Efficacy and safety of bevacizumab combined with EGFR‐TKIs in advanced non‐small cell lung cancer: A meta‐analysis
por: Yang, Yifan, et al.
Publicado: (2021)

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2017)

Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy
por: GAO, ZHENHUA, et al.
Publicado: (2014)

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p8jra3d9srfq9gkj6cgri08qs0